Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Peripheral Arterial Disease: Features

Interview
The Economic Costs and Patient Consequences of Amputation as a Treatment for Critical Limb Ischemia
09/19/2024
Mary Yost, MBA, president and cofounder of The Yost Group, spoke with VDM about her AMP 2024 presentation on the consequences of amputation as a treatment for patients with CLI.
Mary Yost, MBA, president and cofounder of The Yost Group, spoke with VDM about her AMP 2024 presentation on the consequences of amputation as a treatment for patients with CLI.
Mary Yost, MBA, president and...
09/19/2024
Vascular Disease Management
Dr Tahara
AMP 2024
First-in-Human Case for SLT IVUS Support Crossing Catheter in Complex CLTI Cases With EUS Guidance
09/19/2024
Watch as Dr. Bob Tahara discusses his AMP 2024 presentation.
Watch as Dr. Bob Tahara discusses his AMP 2024 presentation.
Watch as Dr. Bob Tahara...
09/19/2024
Vascular Disease Management
Dr Craig Walker
AMP 2024
The Gore® Viabahn® Stent Graft in the Superficial Femoral Artery for In-Stent Restenosis
09/19/2024
In this video, Dr. Craig Walker discusses his presentation at AMP 2024 on how the Gore Viabahn stent graft is used for in-stent restenosis.
In this video, Dr. Craig Walker discusses his presentation at AMP 2024 on how the Gore Viabahn stent graft is used for in-stent restenosis.
In this video, Dr. Craig Walker...
09/19/2024
Vascular Disease Management
Dr Ramon Varcoe
AMP 2024
LIFE-BTK Further Analysis; 12-month RESOLV Data
09/18/2024
In this video recorded at AMP 2024, Dr. Ramon Varcoe discusses 2 of his AMP presentations on the results and indications of the LIFE-BTK and RESOLV studies.
In this video recorded at AMP 2024, Dr. Ramon Varcoe discusses 2 of his AMP presentations on the results and indications of the LIFE-BTK and RESOLV studies.
In this video recorded at AMP...
09/18/2024
Vascular Disease Management
Dr Thomas Zeller
AMP 2024
SPORTS: Drug-Eluting Stent or Primary Bare Nitinol Stent Application vs Drug-Coated Balloons in Long SFA Lesions; HEAL Study Update
09/18/2024
In this video, Dr. Thomas Zeller discusses the latest results from the SPORTS trial and the HEAL study.
In this video, Dr. Thomas Zeller discusses the latest results from the SPORTS trial and the HEAL study.
In this video, Dr. Thomas Zeller...
09/18/2024
Vascular Disease Management
Dr. Michael Siah
AMP 2024
ZilverPASS 5-year Results; Deep Vein Arterialization: History and Rationale
09/17/2024
Watch as Dr. Michael Siah discusses 2 of his AMP 2024 presentations on ZilverPASS and DVA.
Watch as Dr. Michael Siah discusses 2 of his AMP 2024 presentations on ZilverPASS and DVA.
Watch as Dr. Michael Siah...
09/17/2024
Vascular Disease Management
Zola N'Dandu, MD
AMP 2024
Pooled Analysis of the DETOUR System; Risk Factors in CLI Patients That May Require DVA
09/17/2024
In this video, Dr. Zola N'Dandu discusses two of his AMP 2024 presentations.
In this video, Dr. Zola N'Dandu discusses two of his AMP 2024 presentations.
In this video, Dr. Zola N'Dandu...
09/17/2024
Vascular Disease Management
Mary Yost
AMP 2024
What Is the Impact of Amputation as a Treatment for CLI? Economic Costs and Patient Consequences
09/16/2024
Watch as Mary Yost, MBA, cofounder of The Yost Group, discusses her AMP 2024 presentation on the consequences of amputation as a treatment for patients with critical limb ischemia.
Watch as Mary Yost, MBA, cofounder of The Yost Group, discusses her AMP 2024 presentation on the consequences of amputation as a treatment for patients with critical limb ischemia.
Watch as Mary Yost, MBA,...
09/16/2024
Vascular Disease Management
Dr Thomas Davis
AMP 2024
CLI Subgroup Analysis From the US SAFE-DCB Registry: Final 3-year Follow-up Results
09/12/2024
In this video recorded at AMP 2024, Dr. Thomas Davis discusses his presentation on the SAFE-DCB registry, a prospective, multicenter, single-arm, real-world US registry assessing the Lutonix 035 drug-coated balloon.
In this video recorded at AMP 2024, Dr. Thomas Davis discusses his presentation on the SAFE-DCB registry, a prospective, multicenter, single-arm, real-world US registry assessing the Lutonix 035 drug-coated balloon.
In this video recorded at AMP...
09/12/2024
Vascular Disease Management
Dr Eric Secemsky
AMP 2024
Variation in Revascularization Strategies for CLTI: A Nationwide Analysis of Medicare Beneficiaries
09/11/2024
In this video recorded at AMP 2024, interventional cardiologist Dr. Eric Secemsky discusses a recent analysis of Medicare beneficiaries undergoing endovascular treatment for CLTI in both high- and low-volume facilities.
In this video recorded at AMP 2024, interventional cardiologist Dr. Eric Secemsky discusses a recent analysis of Medicare beneficiaries undergoing endovascular treatment for CLTI in both high- and low-volume facilities.
In this video recorded at AMP...
09/11/2024
Vascular Disease Management

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement